EGFR and non-small cell lung carcinoma: Patients with resected EGFR-mutant NSCLC showed significantly improved DFS when treated with adjuvant EGFR-TKIs compared with non-EGFR-TKI treatment, regardless of EGFR mutation type or EGFR-TKI generation and stage, with tolerated AEs.